Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.61 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 3/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16621423 | 0.88 | NOD1 (0.79) | NOD1FAAHGLP1RSLC6A5 | |
| SCHEMBL16620474 | 0.87 | NOD1 (0.82) | NOD1FAAHGLP1RSLC6A5 | |
| SCHEMBL12807270 | 0.87 | NOD1 (0.82) | NOD1FAAHGLP1RSLC6A5 | |
| SCHEMBL15002725 | 0.87 | NOD1 (0.82) | NOD1FAAHGLP1RSLC6A5 | |
| SCHEMBL13640755 | 0.87 | NOD1 (0.82) | NOD1FAAHGLP1RSLC6A5 | |
| SCHEMBL21360278 | 0.86 | FOLH1 (0.58) | NOD1FOLH1RIMKLANAALAD2 | |
| SCHEMBL15451426 | 0.86 | NOD1 (0.61) | NOD1FOLH1RIMKLANAALAD2SLC6A5 | |
| SCHEMBL9005518 | 0.85 | FOLH1 (0.62) | NOD1FOLH1RIMKLANAALAD2 | |
| SCHEMBL20539229 | 0.85 | FOLH1 (0.62) | NOD1FOLH1RIMKLANAALAD2 | |
| SCHEMBL9005526 | 0.85 | FOLH1 (0.62) | NOD1FOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10834951-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2020-11-17 | — | — | US | claimed |
| EP-3057449-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-02-28 | — | — | EP | claimed |
| US-20170258122-A1 | Organic Compounds | GIVAUDAN S.A. (CH) | 2017-09-14 | — | — | US | claimed |
| EP-3057449-A1 | ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2016-08-24 | — | — | EP | claimed |
| WO-2015050535-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2015-04-09 | — | — | WO | claimed |
| WO-2015049294-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2015-04-09 | — | — | WO | claimed |
| US-10834951-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2020-11-17 | — | — | US | disclosed |
| CN-105592721-B | Organic compounds | 奇华顿股份有限公司 | 2020-03-17 | — | — | CN | disclosed |
| EP-3057449-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-20170258122-A1 | Organic Compounds | GIVAUDAN S.A. (CH) | 2017-09-14 | — | — | US | disclosed |
| EP-3057449-A1 | ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2016-08-24 | — | — | EP | disclosed |
| CN-105592721-A | Organic compounds | GIVAUDAN SA | 2016-05-18 | — | — | CN | disclosed |
| WO-2015050535-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015049294-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10834951-B2 | Organic compounds | CBR3, C9, AOC2 | NOD1 1614/4885MMP2 4040/4885MMP9 3961/4885 |
| US-20170258122-A1 | Organic Compounds | CBR3, C9, AOC2 | NOD1 1614/4885MMP2 4040/4885MMP9 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.